Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Up 30.9% in November

Synaptogenix, Inc. (NASDAQ:SNPX) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 7,200 shares, a growth of 30.9% from the November 15th total of 5,500 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average trading volume of 23,800 shares, the days-to-cover ratio is currently 0.3 days.

Synaptogenix Stock Performance

NASDAQ SNPX traded up $0.01 during trading on Friday, hitting $2.69. The stock had a trading volume of 1,949 shares, compared to its average volume of 15,190. The firm has a 50 day moving average price of $2.93 and a 200 day moving average price of $3.52. Synaptogenix has a twelve month low of $2.32 and a twelve month high of $8.78.

Synaptogenix (NASDAQ:SNPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($4.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.95) by ($2.63).

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.